Screener
Neurocrine Biosciences NBIX Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions) | March 31,2026 | December 31,2025 |
|---|---|---|
| Sales rebates and reserves | $231.3 | $226.0 |
| Current income taxes payable | 186.4 | 68.0 |
| Accrued development costs | 110.7 | 101.3 |
| Accrued employee related costs | 81.7 | 128.8 |
| Current branded prescription drug fee | 42.9 | 45.3 |
| Accounts payable and other accrued liabilities | 120.0 | 104.9 |
| Total accounts payable and accrued liabilities | $773.0 | $674.3 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's accrued manufacturing costs?
- Neurocrine Biosciences (NBIX) reported accrued manufacturing costs of $81.7M in Q1 2026.
- How has Neurocrine Biosciences's accrued manufacturing costs changed year-over-year?
- Neurocrine Biosciences's accrued manufacturing costs increased by 42.1% year-over-year, from $57.5M to $81.7M.
- What is the long-term trend for Neurocrine Biosciences's accrued manufacturing costs?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's accrued manufacturing costs has grown at a 20.9% compound annual growth rate (CAGR), from $72.8M to $128.8M.
Ask your AI about Neurocrine Biosciences's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude